← Leaderboards
James Shorter
Mayo Clinic Jacksonville
$11,511,778
Attributed
$14,816,890
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2007–25$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,816,890 · 11
By mechanism
R01$6,022,084 · 2
RF1$3,360,074 · 1
R21$3,072,232 · 7
DP2$2,362,500 · 1
Top collaborators
- Wilfried Rossoll3 shared
- Christopher James Donnelly1 shared
- Robert G Kalb1 shared
Most similar at Mayo Clinic Jacksonville
Same institution · by research overlap
- Andrew J Saykin$38,010,806
- Thomas L Kukar$7,998,572
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsNeurodegenerative DisordersNerve DegenerationVariantAlzheimer&AposProtein MisfoldingAmyloidStructureEngineeringProtein AggregationAtp PhosphohydrolaseProtein Tdp-43LinkParkinson DiseaseMolecular ChaperonesYeastsToxic EffectNeuronsRattusCollaborationsAlpha SynucleinBaseIn VivoAmyotrophic Lateral Sclerosis
Grant awards (29)
Defining short RNA therapeutics that combat TDP-43 proteinopathy connected to AD and ADRDs.$3,360,074
RF1 · FY2025 · AG · contact PI
Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS$705,885
R01 · FY2025 · AG
Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS$693,758
R01 · FY2024 · AG
Defining mechanisms of AAA+ disaggregases$341,407
R01 · FY2024 · GM · contact PI
Nuclear import receptors as modifiers of TDP-43 phase transition and toxicity in FTD/ALS$730,483
R01 · FY2023 · AG
Defining mechanisms of AAA+ disaggregases$341,592
R01 · FY2023 · GM · contact PI
Engineering therapeutic TRIM11 disaggregases for Alzheimer's Disease-Related Dementias (ADRDs)$446,875
R21 · FY2022 · AG · contact PI
Defining mechanisms of AAA+ disaggregases$341,771
R01 · FY2022 · GM · contact PI
Defining mechanisms of AAA+ disaggregases$341,860
R01 · FY2021 · GM · contact PI
Programming human protein disaggregases against FTD$445,875
R21 · FY2020 · AG · contact PI
Defining the mechanistic basis of a prion disaggregase$339,308
R01 · FY2020 · GM · contact PI
Isolating small-molecule enhancers of the human alpha-synuclein disaggregase machinery$240,441
R21 · FY2020 · AG · contact PI
Defining the mechanistic basis of a prion disaggregase$339,308
R01 · FY2019 · GM · contact PI
Isolating small-molecule enhancers of the human alpha-synuclein disaggregase machinery$200,222
R21 · FY2019 · AG · contact PI
Defining the mechanistic basis of a prion disaggregase$339,308
R01 · FY2018 · GM · contact PI
Isolating small-molecule enhancers of HtrA1, an alpha-synuclein disaggregase$240,464
R21 · FY2018 · NS · contact PI
Defining the mechanistic basis of a prion disaggregase$339,308
R01 · FY2017 · GM · contact PI
Exploring and enhancing Karyopherin beta-2 disaggregate activity$236,398
R21 · FY2017 · NS · contact PI
Isolating small-molecule enhancers of HtrA1, an alpha-synuclein disaggregase$200,245
R21 · FY2017 · NS · contact PI
Defining the mechanistic basis of a prion disaggregase$291,666
R01 · FY2016 · GM · contact PI
Exploring and enhancing Karyopherin beta-2 disaggregate activity$195,953
R21 · FY2016 · NS · contact PI
Defining the mechanistic basis of a prion disaggregase$291,908
R01 · FY2015 · GM · contact PI
Defining the mechanistic basis of a prion disaggregase$292,145
R01 · FY2014 · GM · contact PI
Defining the mechanistic basis of a prion disaggregase$292,377
R01 · FY2013 · GM · contact PI
Generating SEVI disaggregases to prevent HIV infection$189,800
R21 · FY2013 · HD · contact PI
Generating SEVI disaggregases to prevent HIV infection$240,000
R21 · FY2012 · HD · contact PI
Exploring mechanisms of TDP-43 aggregation and disaggregation$237,000
R21 · FY2010 · NS · contact PI
Exploring mechanisms of TDP-43 aggregation and disaggregation$198,959
R21 · FY2009 · NS · contact PI
Amyloid elimination by Hsp104 and substrate-optimized variants$2,362,500
DP2 · FY2007 · OD · contact PI